{"publisher":"LL-37 Rx","product":"LL-37","preparedAt":"2026-11-07","reviewStatus":"Research drafts; medical review has not been claimed","facts":[{"label":"Research finding 1","text":"The early randomized study enrolled 34 people and investigated topical LL37 for venous leg ulcers over a four-week treatment period.","href":"https://pubmed.ncbi.nlm.nih.gov/25041740/"},{"label":"Research finding 2","text":"Some lower-concentration groups improved healing predictors; the highest-concentration group did not differ from placebo.","href":"https://pubmed.ncbi.nlm.nih.gov/25041740/"},{"label":"Research finding 3","text":"HEAL LL-37 randomized149 participants;148 were treated and144 entered the full efficacy-analysis set. It compared topical LL-37 plus compression with placebo plus compression.","href":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9298190/"},{"label":"Research finding 4","text":"The phaseIIb full-cohort analysis did not find a significant healing improvement with LL37.","href":"https://pubmed.ncbi.nlm.nih.gov/34687253/"}],"sources":[{"title":"Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial.","href":"https://pubmed.ncbi.nlm.nih.gov/25041740/"},{"title":"Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial.","href":"https://pubmed.ncbi.nlm.nih.gov/34687253/"},{"title":"Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks","href":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}],"guides":[{"title":"Antimicrobial activity is not proof of infection treatment","url":"https://ll37rx.com/research-guides/antimicrobial-lab-versus-infection-treatment","description":"How to distinguish LL-37 laboratory findings from evidence needed to replace or supplement clinical anti-infective care.","date":"2026-11-07"},{"title":"Can bacteria be less susceptible to LL-37? A surface-chemistry example","url":"https://ll37rx.com/research-guides/bacterial-surface-susceptibility","description":"Why a host-defense origin does not establish resistance-proof activity against every bacterial strain.","date":"2026-11-07"},{"title":"LL-37 and biofilms: identify the model before the claim","url":"https://ll37rx.com/research-guides/biofilm-models-what-was-tested","description":"A reader’s guide to attachment, biofilm biomass, bacterial growth and the limits of laboratory antibiofilm findings.","date":"2026-11-07"},{"title":"LL-37 and cancer: opposite findings can both require context","url":"https://ll37rx.com/research-guides/cancer-research-context-dependent","description":"Separate ovarian and colon experimental models, human tissue associations and a tiny intratumoral trial record.","date":"2026-11-07"},{"title":"hCAP-18 and LL-37: why the precursor is not the finished peptide","url":"https://ll37rx.com/research-guides/hcap18-precursor-processing","description":"Understand the original protein-processing research and why gene expression does not establish administered-peptide benefit.","date":"2026-11-07"},{"title":"LL-37 and innate immunity: activation is not automatically beneficial","url":"https://ll37rx.com/research-guides/innate-immunity-inflammation-context","description":"Understand why LL-37’s immune signaling cannot be reduced to a general immune-boosting claim.","date":"2026-11-07"},{"title":"LL-37 in periodontal fluid: delivery depends on what happens locally","url":"https://ll37rx.com/research-guides/periodontal-fluid-proteolysis","description":"Read the gingival-fluid and saliva experiments without turning them into a periodontitis treatment claim.","date":"2026-11-07"},{"title":"LL-37 as an autoantigen: what the psoriasis T-cell study means","url":"https://ll37rx.com/research-guides/psoriasis-adaptive-autoantigen","description":"Understand antigen recognition without confusing it with allergy, an injection-risk estimate or an immune-health benefit.","date":"2026-11-07"},{"title":"Rosacea research shows why peptide processing matters","url":"https://ll37rx.com/research-guides/rosacea-peptide-processing","description":"Separate human skin observations and mouse experiments from claims about using LL-37 for redness or skin repair.","date":"2026-11-07"},{"title":"LL-37 safety: route and formulation belong in the first question","url":"https://ll37rx.com/research-guides/route-specific-safety-regulatory-record","description":"Read FDA’s current safety entry without mistaking withdrawn nomination status or topical tolerability for approval.","date":"2026-11-07"},{"title":"LL-37 wound-healing trials: the larger study was negative overall","url":"https://ll37rx.com/research-guides/venous-ulcer-trials-full-cohort","description":"Read the small early topical trial alongside HEAL LL-37, including its full-cohort result and post hoc subgroup.","date":"2026-11-07"},{"title":"Vitamin D and cathelicidin: a pathway is not a supplement prescription","url":"https://ll37rx.com/research-guides/vitamin-d-cathelicidin-pathway","description":"Read the human-cell mechanism studies without assuming vitamin D, endogenous LL-37 and injected peptide are interchangeable.","date":"2026-11-07"}]}